Abstract Library

#4457 Primary mixed hepatocellular carcinoma-neuroendocrine carcinoma: A case report

Introduction: Mixed epithelial neoplasms (MiNENs) are characterised by the coexistence of neuroendocrine and non-neuroendocrine components within a single tumour, each discernible histologically and immunohistochemically, with a minimum tumour proportion of 30%. Primary hepatic MiNENs are exceedingly rare entities.

Conference:

Presenting Author: Tang Y

Authors: Wang Y, Wang R, Yi X, Guo M, Tang Y,

Keywords: pancreatic neuroendocrine tumour, functional, parathyroid hormone related peptide,

#3886 Large cell neuroendocrine carcinoma subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression

Introduction: Large cell neuroendocrine carcinoma (LCNEC) accounts for 1-3% of all types of lung cancer and is, similar to small-cell lung cancer (SCLC), a high-grade tumor with poor prognosis. pRb can also be used to subclassify LCNEC into SCLC-like and NSCLC-like. SCLC can be classified in 4 transcriptomic subtypes (NEUROD1high, ASCL1high, POU2F3high, YAP1high), which may have therapeutic implications. It is unclear whether these subtypes are also found in LCNEC and if they correlate with pRb expression.

Conference:

Presenting Author: Heijboer F

Authors: Rijnsburger N, Heijboer F, Derks J, Hermans B, Hillen L,

Keywords: LCNEC, pulmonary, immunohistochemistry, pathology, pRb, transcription factors,

#3755 Large cell neuroendocrine carcinoma of the breast

Introduction: Primary neuroendocrine breast carcinomas are rare and little-known tumors. They account for only 2 % to 5 % of breast cancers. Diagnosis is based on neuroendocrine architecture associated with the expression of neuroendocrine markers.

Conference:

Presenting Author:

Authors: Samia K, Siham C, Fatima H,

Keywords: large cell neuroendocrine carcinoma, neuroendocrine marker, chromogranin, synaptophysin, mastectomy,

#3702 The role of the somatostatin analogues in large cell neuroendocrine carcinomas treatment

Introduction: Large cell neuroendocrine carcinoma (LCNEC) is still a poorly studied disease with low somatostatin receptors expression, so we have scant data on the effectiveness of the somatostatin analogues (SSA) in this disease.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Artamonova E, Delektorskaya V, Yemelyanova G, Markovich A,

Keywords: NEC, SSTR, somatostatin analogues, large cell carcinoma, SSA, LCNEC, somatostatin receptor,

#3554 Stereotactic radiosurgery of brain metastases in large cell neuroendocrine carcinoma of the lung

Introduction: Stereotactic radiosurgery (SRS) is an established treatment of brain metastases (BM) in non-small cell lung cancer (NSCLC) whereas small cell lung cancer (SCLC) is usually treated with whole-brain irradiation (WBI). There is no consensus on treatment of BM in large cell neuroendocrine carcinoma of the lung (LCNEC).

Conference:

Presenting Author: Suppli M

Authors: Suppli M, Langer S, Persson G, Møller S,

Keywords: LCNEC, Radiosurgery, brain metastasis, radiotherapy,